Shilpa Medicare jumps on getting CDSCO approval for hemostatic spray of Tranexamic Acid
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Shilpa Medicare is currently trading at Rs. 392.25, up by 16.85 points or 4.49% from its previous closing of Rs. 375.40 on the BSE.
The scrip opened at Rs. 385.00 and has touched a high and low of Rs. 397.05 and Rs. 383.15 respectively. So far 12776 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 657.95 on 14-Oct-2021 and a 52 week low of Rs. 367.20 on 29-Aug-2022.
Last one week high and low of the scrip stood at Rs. 397.05 and Rs. 372.75 respectively. The current market cap of the company is Rs. 3410.45 crore.
The promoters holding in the company stood at 50.01%, while Institutions and Non-Institutions held 16.40% and 33.59% respectively.
Shilpa Medicare has received CDSCO approval for its successful innovation of first in world topical hemostatic spray of Tranexamic Acid. This novel formulation of spray is simple, easy to carry, convenient to use and a lifesaving tool. Clinically proven in humans and validated in robust swine trauma model. The product is approved for the usage of reducing or preventing hemorrhage and to reduce the need of replacement therapy during accidental and domestic injury.
The product is protected by granted patents in India till 2037 and in US, Australia, Russia and South Africa till 2038. Shilpa is continuously pursuing patent prosecution in other countries and for further protection.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
